$9.05
2.49% yesterday
Nasdaq, Nov 25, 09:17 pm CET
ISIN
US67576A1007
Symbol
OCUL
Sector
Industry

Ocular Therapeutix Inc Stock price

$9.09
-2.05 18.40% 1M
+3.30 56.86% 6M
+4.63 103.81% YTD
+6.86 307.62% 1Y
+2.21 32.12% 3Y
+5.91 185.85% 5Y
-9.10 50.03% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.26 2.94%
ISIN
US67576A1007
Symbol
OCUL
Sector
Industry

Key metrics

Market capitalization $1.43b
Enterprise Value $1.08b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 17.53
P/S ratio (TTM) P/S ratio 23.26
P/B ratio (TTM) P/B ratio 4.05
Revenue growth (TTM) Revenue growth 6.45%
Revenue (TTM) Revenue $61.44m
EBIT (operating result TTM) EBIT $-141.25m
Free Cash Flow (TTM) Free Cash Flow $-114.06m
Cash position $427.22m
EPS (TTM) EPS $-1.32
P/E forward negative
P/S forward 22.41
EV/Sales forward 16.89
Short interest 8.16%
Show more

Is Ocular Therapeutix Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Ocular Therapeutix Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Ocular Therapeutix Inc forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Ocular Therapeutix Inc forecast:

Buy
100%

Financial data from Ocular Therapeutix Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
61 61
6% 6%
100%
- Direct Costs 5.78 5.78
18% 18%
9%
56 56
5% 5%
91%
- Selling and Administrative Expenses 90 90
23% 23%
147%
- Research and Development Expense 103 103
76% 76%
167%
-137 -137
74% 74%
-224%
- Depreciation and Amortization 3.79 3.79
50% 50%
6%
EBIT (Operating Income) EBIT -141 -141
73% 73%
-230%
Net Profit -174 -174
160% 160%
-284%

In millions USD.

Don't miss a Thing! We will send you all news about Ocular Therapeutix Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ocular Therapeutix Inc Stock News

Neutral
GlobeNewsWire
9 minutes ago
BEDFORD, Mass. , Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced participation in several investor and scientific conferences being held...
Neutral
Seeking Alpha
12 days ago
Ocular Therapeutix, Inc. (OCUL) Q3 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
13 days ago
BEDFORD, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced upcoming presentations at the Jefferies London Healthcare Conference and...
More Ocular Therapeutix Inc News

Company Profile

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Head office United States
CEO Pravin Dugel
Employees 267
Founded 2006
Website www.ocutx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today